Alpha7 nicotinic acetylcholine receptor-specific agonist DMXBA (GTS-21) attenuates Aβ accumulation through suppression of neuronal γ-secretase activity and promotion of microglial amyloid-β phagocytosis and ameliorates cognitive impairment in a mouse model of Alzheimer's disease.

Takata, Kazuyuki

Alpha7 nicotinic acetylcholine receptor-specific agonist DMXBA (GTS-21) attenuates Aβ accumulation through suppression of neuronal γ-secretase activity and promotion of microglial amyloid-β phagocytosis and ameliorates cognitive impairment in a mouse model of Alzheimer's disease. [electronic resource] - Neurobiology of aging 02 2018 - 197-209 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1558-1497

10.1016/j.neurobiolaging.2017.10.021 doi


Alzheimer Disease--complications
Amyloid Precursor Protein Secretases--metabolism
Amyloid beta-Peptides--immunology
Animals
Benzylidene Compounds--pharmacology
Brain--metabolism
Cells, Cultured
Cognitive Dysfunction--drug therapy
Disease Models, Animal
Humans
Mice, Transgenic
Microglia--immunology
Neuroblastoma--metabolism
Phagocytosis--drug effects
Pyridines--pharmacology
Rats
Tumor Cells, Cultured
alpha7 Nicotinic Acetylcholine Receptor--agonists